Shots:
- Natera has entered into collaboration with Angiex to use longitudinal Signatera testingfor circulating tumor DNA (ctDNA) to assess treatment response monitoring during AGX101 treatment
- AGX101 is designed to target TM4SF1-expressing tumor cells & tumor-associated endothelial cells, delivering a cytotoxic payload to both the tumor & its vasculature
- Angiex is conducting a P-I trial of AGX101 in patients with unresectable, locally advanced or metastatic solid tumors, with the study currently enrolling participants
Ref: Businesswire | Image: Natera & Angiex | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
